WEST

PA

19428

FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# OMB APPROVAL OMB Number: 32350104 Estimated average burden

0.5

hours per response:

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fairmount Funds Managemen LLC	2. Date of Requiring (Month/Date 09/12/20	Statement ay/Year)	3. Issuer Name and Ticker or Trading Symbol Zenas BioPharma, Inc. [ ZBIO ]								
(Last) (First) (Middle) 200 BARR HARBOR DRIVE			4. Relationship of Reporting Issuer (Check all applicable)  Director	ng Person(s			Amendment, d (Month/Day/	Date of Original Year)			
SUITE 400	_		Officer (give title below)	Other below)	(specify		eck Applicable	int/Group Filing Line) by One Reporting			
(Street) WEST CONSHOHOCKEN PA 19428						v	Person	by More than One			
(City) (State) (Zip)											
7	able I - No	n-Derivati	ive Securities Benef	icially O	wned						
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	Form: [ (D) or li	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  4. Nature of Indirect Beneficial Ownership (Instr. 5)						
Common Stock			287,915	]	I By Fairmount Healthcare Fund I LP <sup>(1)</sup>		ealthcare Fund II				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of S Underlying Derivative So (Instr. 4)				Indirect Beneficial Ownership (Instr.				
	Date	Expiration		Amount or Number of	Derivat Securit	ive	or Indirect (I) (Instr. 5)	9,			
	Exercisable	Date	Title	Shares							
Series Seed Convertible Preferred Stock	(2)	(2)	Common Stock	41,130	(2)		I	By Fairmount Healthcare Fund II LP <sup>(1)</sup>			
Series A Convertible Preferred Stock	(3)	(3)	Common Stock	252,890	(3)		I	By Fairmount Healthcare Fund II LP <sup>(1)</sup>			
Series B Convertible Preferred Stock	(4)	(4)	Common Stock	709,794	(4)		I	By Fairmount Healthcare Fund II LP <sup>(1)</sup>			
Series C Convertible Preferred Stock	(5)	(5)	Common Stock	301,077	(5)		I	By Fairmount Healthcare Fund II LP <sup>(1)</sup>			
1. Name and Address of Reporting Person*  Fairmount Funds Management	t LLC										
(Last) (First) (M 200 BARR HARBOR DRIVE SUITE 400	liddle)										
(Street)		-									

CONSHOL	HOCKEN						
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*  Fairmount Healthcare Fund II L.P.							
(Last) 200 BARR SUITE 400	(First) R HARBOR DRIVE )	(Middle)					
(Street) WEST CONSHOL	HOCKEN <sup>PA</sup>	19428					
(City)	(State)	(Zip)					
Name and Address of Reporting Person* <u>Kiselak Tomas</u>							
(Last) 200 BARR SUITE 400	(First) L HARBOR DRIVE )	(Middle)					
(Street) WEST CONSHOL	HOCKEN <sup>PA</sup>	19428					
(City)	(State)	(Zip)	_				
	Address of Reporting Peter Evan	Person*					
(Last) 200 BARR SUITE 400	(First) R HARBOR DRIVE )	(Middle)					
(Street) WEST CONSHOL	HOCKEN PA	19428					
(City)	(State)	(Zip)					

### **Explanation of Responses:**

- 1. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- 2. Each share of Series Seed Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 8.6831-for-1 basis and has no expiration date. The Series Seed Convertible Preferred Stock will automatically convert into common stock upon the closing of the Company's initial public offering.
- 3. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 8.6831-for-1 basis and has no expiration date. The Series A Convertible Preferred Stock will automatically convert into common stock upon the closing of the Company's initial public offering.
- 4. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 8.6831-for-1 basis and has no expiration date. The Series B Convertible Preferred Stock will automatically convert into common stock upon the closing of the Company's initial public offering.
- 5. Each share of Series C Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 8.6831-for-1 basis and has no expiration date. The Series C Convertible Preferred Stock will automatically convert into common stock upon the closing of the Company's initial public offering.

### Remarks

Fairmount may be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.

/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC	09/12/2024
/s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II LP	09/12/2024
/s/ Tomas Kiselak	09/12/2024

/s/ Peter Harwin

09/12/2024

\*\* Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.